Welcome, visitor! [ Login

Dragon Pharmaceuticals Appoints Rita Jervis as VP Corporate Development


Dragon Pharmaceuticals Inc. is pleased to announce that it has appointed Ms. Rita Jervis as VP Corporate Development. Ms. Jervis will be responsible for leading the company’s strategic planning, business development, and investor relations initiatives.

Ms. Jervis brings to her position 14 years of planning and operations experience in the biotechnology sector. In her position as President of Jervis Associates, a management consulting firm established in 1991 to provide interim executive and consulting services to emerging health sector companies, Ms. Jervis has held numerous executive and managing director positions in R&D, contract research, and venture capital firms. In addition, Ms. Jervis recently served as Executive Director of the B.C. Biotechnology Alliance and, prior to establishing Jervis Associates, held project and marketing management positions with QLT Inc. (Nasdaq: QLTI, TSE: QLT)

Dragon Pharmaceuticals also announced today that it has received approval from Standard & Poor’s to trade in 35 U.S. states under the Blue Sky rules and regulations. Dragon’s company listing was published in the January 2, 2001 edition of the Standard & Poor’s Corporation Records, a recognized securities manual widely relied upon by investment officers, pension fund managers, registered representatives, and other financial service professionals to facilitate secondary market trading.

About Dragon Pharmaceuticals Inc.
Dragon Pharmaceuticals is an international biopharmaceutical corporation engaged in the discovery, development and marketing of therapies for infectious diseases, cancer, and cardiovascular diseases. Using proprietary protein expression technology, Dragon has become one of the world’s lowest cost producers of EPO (Erythropoietin), and is currently in the process of applying its technology to six additional generic drugs. Dragon intends to become a leading biotechnology company by delivering generic drugs at affordable prices as well as by developing and commercializing proprietary drugs with worldwide patent potential.

Legal Dragon Pharma

Dragon Pharma is a pharmaceutical company: Deca 300 on Sale – manufacturing and exporting from EU.

No Tags

766 total views, 1 today


  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Growth in International EPO Sales

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced the receipt of EPO sales orders from international markets outside of China totaling $937,500 in the first quarter of 2002, representing a 113% increase over total year international sales of $440,125 in 2001. To date, the Company has completed EPO shipments for $847,500 of first quarter orders, […]

  • Dragon Pharma Sells Polymun Development

    Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) announced today that the Company has sold its Development and Manufacturing Agreement with Polymun Scientific Immunbiologische Forschung GmBh (“Polymun”) to AS Biotech AG, a Swiss company, for US$1 million. Prior to the acquisition of Oriental Wave Holding Limited in early 2005, Dragon entered into a […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics